2020 FH Global Summit

Familial hypercholesterolemia:
Driving solutions to prevent inherited cardiovascular disease
Our 8th annual FH Global Summit was convened as a series of eight monthly virtual sessions focused on driving new solutions to prevent inherited cardiovascular disease from September 2020 - May 2021. Over the course of this conference, leading experts from multiple disciplines shared the latest research to advance scientific understanding and optimize care for people at risk for premature heart attacks, stroke and heart disease. Each attendee was selected because of their unique views and the contribution they can make to the discussion. The FH Foundation believes that collectively we can develop the solutions to stop premature heart disease.

Co-Chairs and Co-Hosts


Joshua W. Knowles, MD, PhD
CO-CHAIR
Daniel J. Rader, MD
CO-CHAIR
Katherine A. Wilemon
CO-HOST
Mary P. McGowan, MD
CO-HOST

Sessions


The FH Global Summit bridges the gap between science, clinical practice and the general public by sharing data and perspectives that inform, inspire and create action across a broad, passionate FH community. Below are recordings from the 2020 FH Global Summit.


Session 1 - The Future of Genetics and Heart Disease
SESSION 1
The Future of Genetics and Heart Disease
The inaugural session of the FH Foundation’s 2020 FH Global Summit will honor Dr. Robert A. Hegele with the 2020 FH Pioneer Award for his achievements in cardiovascular genetics including key discoveries of the genetic basis of several human lipid disorders. Dr. Hegele will give a keynote address on the drivers of inherited heart disease, which will be followed by a conversation with Drs. Daniel Rader and Joshua Knowles and audience Q & A.

Session Details

Session 2 - Unlocking the potential of precision health for diverse populations
SESSION 2
Unlocking the Potential of Precision Health for Diverse Populations
Precision medicine holds the promise to revolutionize clinical care but only if all populations can share in those benefits. While FH and high lipoprotein(a) impact all races and ethnicities, contemporary studies (including from the FH Foundation’s CASCADE FH longitudinal study) continue to demonstrate unacceptable disparities in care particularly for Black, Asian and Latin populations and for women. Join Dr. Latrice Landry for a provocative discussion about overcoming the challenges of disparities in care.

Session Details

Session 3 - Can behavioral economics drive cardiovascular disease prevention?
SESSION 3
Can Behavioral Economics Drive Cardiovascular Disease Prevention?
Guidelines and therapies can be effective and still not be implemented if barriers to prescribing are not removed. An individual “patient” spends 5,000 hours without a healthcare provider making their own daily choices to improve their health or take their medication. Is it possible to align these stakeholders? Join us to hear from Dr. Kevin Volpp about how health incentives, behavioral economics, and “nudges” can improve cardiovascular health. This session will include a dynamic discussion with diverse healthcare stakeholders.

Session Details

Session 4
SESSION 4
Lp(a) and Drivers of Inherited Risk
Lipoprotein (a), Lp(a), is an important independent risk factor for premature atherosclerotic cardiovascular disease (ASCVD), including heart attacks, stroke and calcific aortic valve stenosis. Guidelines on whom to screen for Lp(a) are evolving and new therapies are emerging.

Session Details

Session 5
SESSION 5
New Frontiers of FH Care
Can gene editing with CRISPR technology help fight cardiovascular disease? Can looking beyond the known FH genes help personalize risk assessment? Join Dr. Kiran Musunuru, Penn Medicine, and Dr. Amit V. Khera, Broad Institute, as we discuss and debate.

Session Details

Session 6
SESSION 6
Implementing Innovations in FH Care
Implementation science provides an opportunity to change behaviors of both clinicians and patients. Join Dr. Meghan Lane-Fall, Penn Medicine, Dr. Laney Jones, Geisinger, and Dr. Brian Mittman, Kaiser Permanente, for a dynamic discussion on improving healthcare delivery through implementation science.

Session Details

Session 7
SESSION 7
FH Treatments
According to the FH Foundation national database, over 5 million people with familial hypercholesterolemia and cardiovascular disease do not achieve guideline-recommended LDL-cholesterol levels. Join Dr. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, and our expert roundtable for an overview of new and emerging treatments.

Session Details

Session 8
SESSION 8
Prioritizing solutions to prevent inherited cardiovascular disease
Atheroscelrotic heart disease is the number 1 cause of death worldwide. LDL cholesterol is the single most modifiable risk. 1 in 5 heart attacks under the age of 50 estimated to be caused by familial hypercholesterolemia. Lipoprotein(a) is also a significant genetic risk factor for heart attacks and strokes, however Lp(a) is not routinely screened for today. In the final and 8th session of the FH Global Summit, Katherine Wilemon, founder and CEO of the FH Foundation will highlight solutions to systematically address barriers to life-saving diagnosis and care. Dr. Eric Sijbrands, professor of vascular medicine at the Erasmus MC in Rotterdam, Netherlands, will overview key themes from the summit series and highlight key implications for the field moving forward. Join us as we discuss prioritizing pragmatic solutions and recap key insights from the 2020 FH Global Summit series.

Session Details